Clinical Trial Update: A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating long-term safety and efficacy of adalimumab in intermediate-, posterior-, or panuveitis completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveitis

Drugs mentioned

• ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Uveitis | Phase 3 | Status: COMPLETED | Results posted: 2019-04-04